ArticleJournal of thoracic disease2025
A novel nomogram for predicting mediastinal lymph node metastasis in non-small cell lung cancer: a retrospective analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate assessment of lymph node metastasis (LNM) is crucial for preoperative staging and treatment planning in patients with lung cancer. While previous research has explored LNM risk in non-small cell lung cancer (NSCLC), clinical validation of multifactorial predictive models is lacking. This study aimed to develop and validate a dynamic nomogram for predicting LNM in NSCLC patients. Methods: We retrospectively analysed 619 NSCLC patients and divided them into training (70%) and validation (30%) groups. Univariate and multivariate ordinal logistic regression analyses identified predictive factors for LNM. Variables were selected via least absolute shrinkage and selection operator (LASSO) regression. A dynamic nomogram was developed on the basis of logistic regression results, and its performance was evaluated through receiver operating characteristic (ROC) curve analysis, calibration plots, and decision curve analysis (DCA). The model was further validated with 1,000 bootstrap resamples. Results: Independent predictors of LNM were ferritin, carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), EGFR exon 19 deletion, tumor size, and tumor location. The nomogram exhibited excellent discriminative ability, with an area under the ROC curve (AUC) of 0.846 in the training group and 0.828 in the validation group. DCA indicated greater net benefits across various LNM risk thresholds. Conclusions: This study presents a dynamic nomogram that integrates EGFR exon 19 deletion and serum ferritin levels, enhancing preoperative staging and aiding treatment decisions for NSCLC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.